Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver

Gene Therapy

Volumn 18, Issue 4, 2011, Pages 403-410

  Qiao, C ^a   Yuan, Z ^a   Li, J ^a,a   He, B ^a   Zheng, H ^a   Mayer, C ^a   Xiao, X ^a  

^a University of North Carolina   (United States)

Author keywords

AAV; gene regulation; microRNA

Indexed keywords

BETA GALACTOSIDASE; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 122; MIR 142; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; GENE EXPRESSION; GENE SEQUENCE; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; BETA-GALACTOSIDASE; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LIVER; LUCIFERASES; MICE; MICRORNAS; MYOSTATIN; ORGAN SPECIFICITY; TRANSGENES;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 79953803239     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.157     Document Type: Article

References (60)

1. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skelet al muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972. (Pubitemid 36857981)
2. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597-1605.
3. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248. (Pubitemid 351724453)
4. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990.
5. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105. (Pubitemid 46935946)
6. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97: 13714-13719.
7. Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skelet al muscle transduction in dogs. Mol Ther 2008; 16: 1944-1952.
8. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253-261. (Pubitemid 34250103)
9. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009; 106: 16363-16368.
10. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-593.
11. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108. (Pubitemid 26339120)
12. Hirata R, Chamberlain J, Dong R, Russell DW. Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol 2002; 20: 735-738. (Pubitemid 34734142)
13. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-2419. (Pubitemid 37193577)
14. High KA. AAV-mediated gene transfer for hemophilia. Ann N Y Acad Sci 2001; 953: 64-74. (Pubitemid 34072977)
15. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X et al. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci USA 2005; 102: 11999-12004. (Pubitemid 41291118)
16. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005; 105: 3079-3086.
17. Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW et al. Regional intravascular delivery of AAV-2-F. IX to skelet al muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464. (Pubitemid 40628186)
18. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18: 643-650.
19. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007; 7: 325-333. (Pubitemid 47595775)
20. Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 2007; 14: 1555-1563.
21. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12: 967-971. (Pubitemid 44175151)
22. Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM et al. To l e r a n c e induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. PLoS One 2009; 4: e6376.
23. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 2007; 110: 1132-1140. (Pubitemid 47281408)
24. Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 2007; 18: 185-194. (Pubitemid 46626458)
25. Zhang TP, Jin DY, Wardrop III RM, Gui T, Maile R, Frelinger JA et al. Tr an sg en e expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther 2007; 14: 429-440.
26. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347. (Pubitemid 43355084)
27. Li H, Lin SW, Giles-Davis W, Li Y, Zhou D, Xiang ZQ et al. A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther 2009; 17: 1215-1224.
28. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828. (Pubitemid 39419909)
29. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 92: 67-75. (Pubitemid 29315987)
30. Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001; 75: 269-277.
31. Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008; 15: 1489-1499.
32. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328. (Pubitemid 41094420)
33. Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006; 80: 426-439.
34. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008; 82: 1154-1161.
35. Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 2003; 13: 807-818. (Pubitemid 36573248)
36. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858. (Pubitemid 33032103)
37. Marquez RT, McCaffrey AP. Advances in microRNAs: implications for gene therapists. Hum Gene Ther 2008; 19: 27-38.
38. Chekanova JA, Belostotsky DA. MicroRNAs and messenger RNA turnover. Methods Mol Biol 2006; 342: 73-85.
39. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
40. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009; 119: 2119-2123.
41. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25: 1457-1467. (Pubitemid 350233144)
42. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may down-regulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
43. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656.
44. Herweijer H, Wolff JA. Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther 2007; 14: 99-107. (Pubitemid 46043816)
45. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53. (Pubitemid 43899488)
46. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19: 1359-1368.
47. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18: 18-26. (Pubitemid 46105461)
48. Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther 2009; 20: 930-942.
49. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-591.
50. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-4152. (Pubitemid 351377775)
51. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111. (Pubitemid 37536759)
52. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytome-galovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573. (Pubitemid 32511077)
53. Lu Y, Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci USA 2009; 106: 17158-17162.
54. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009; 106: 3946-3951.
55. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232. (Pubitemid 28100780)
56. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 2009; 17: 503-510.
57. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 2005; 127: 40-45. (Pubitemid 40704636)
58. Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, Zeller WJ et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002; 6: 272-278. (Pubitemid 36336136)
59. Qiao C, Wang B, Zhu X, Li J, Xiao X. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J Virol 2002; 76: 13015-13027. (Pubitemid 35386985)
60. Yu CY, Yuan Z, Cao Z, Wang B, Qiao C, Li J et al. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009; 16: 953-962.